Bruno Silva-Santos is a Group Leader and Vice-Director of Instituto de Medicina Molecular, and Associate Professor of the Faculty of Medicine of the University of Lisbon. He did his PhD in Immunology at Cancer Research UK and post-doc training post-doc at King’s College London. Since establishing his independent group at iMM, Bruno Silva-Santos has received Starting and Consolidator Grants from the European Research Council (ERC) and Installation and Young Investigator Grants from the European Molecular Biology Organization (EMBO). His research is dedicated to T cells, having dissected novel molecular mechanisms of T-cell differentiation and tumor cell recognition, published in journals such as Science or Nature Immunology, among a total of 77 papers. His translational work was recognized with various awards; and led to a start-up company focused on cancer immunotherapy, Lymphact, recently acquired by GammaDelta Therapeutics (London, UK).